Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter Partners With Reference Lab to Develop Multi-Analyte Assays

NEW YORK, Feb. 13 - Beckman Coulter and Specialty Laboratories have signed a cross-licensing agreement to develop multi-analyte assays for the Beckman Progressive microarray platform, the instrument manufacturer said on Wednesday.

 

Under the deal, Specialty Laboratories will have early access to Beckman Coulter's assay-development technology. Beckman will in turn have access to multi-analyte assays that Specialty may develop as a result.

 

Financial details of the arrangement were not disclosed.

 

The companies expect that testing services resulting from the collaboration may be available by the end of the year.

 

The Beckman technology will allow Specialty Laboratories to produce multiple analytical results from one sample incubation, Specialty Laboratories Chairman and CEO James Peter said in a statement.

 

Specialty Laboratories, based in Santa Monica, Calif., is a clinical reference laboratory that serves hospitals, labs, and physicians. The company also  conducts R&D independently and in conjunction with biotech firms.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.